A role for systemic inflammation in diabetic retinopathy

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 3, 2013, Pages 2384-

  Abcouwer, Steven F ^a   Antonetti, David A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD18 ANTIGEN; CELL ADHESION MOLECULE; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DIABETIC RETINOPATHY; EYE INFLAMMATION; HUMAN; INTRACELLULAR SIGNALING; LEUKOSTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINOPATHY; VISUAL ACUITY;

DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; RHO-ASSOCIATED KINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875671413     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-11977     Document Type: Article

References (5)

1. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18:1450-1452.
2. Huang H, Gandhi JK, Zhong X, et al. TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci. 2013;54:2373-2383.
3. Arita R, Nakao S, Kita T, et al. A key role for ROCK in TNF-a-mediated diabetic microvascular damage. Invest Ophthalmol Vis Sci. 2013; 54:2373-2383.
4. Smith CW. Endothelial adhesion molecules and their role in inflammation. Can J Physiol Pharmacol. 1993;71:76-87.
5. Sfikakis PP, Grigoropoulos V, Emfietzoglou I, et al. Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. Diabetes Care. 2010;33:1523-1528.